Feature | June 07, 2013

Study Suggests New Role for ECMO in Patients With Cardiac Arrest, Profound Shock

Procedure traditionally used during heart surgery and in the ICU may show promise as a rescue strategy for select cardiac arrest patients

June 7, 2013 — Extracorporeal membrane oxygenation (ECMO), a procedure traditionally used during cardiac surgeries and in the intensive care unit (ICU) that functions as an artificial replacement for a patient's heart and lungs, has also been used to as a resuscitation device for cardiac arrest victims in Japan, Taiwan and South Korea. Now, a novel study of this technique in the United States has been completed by researchers at the Perelman School of Medicine at the University of Pennsylvania, indicating a potential role for this intervention to save patients who are unable to be resuscitated through conventional measures.

ECMO directly oxygenates and removes carbon dioxide from the blood, and is used for both respiratory and cardiac failure. The procedure requires 24/7 monitoring and care for the duration of the treatment, but it provides a critical backup for patients whose heart and lungs are so severely diseased or damaged that they can no longer function.

"Over the last decade, we have made great strides in the field of cardiac resuscitation science, including the development of novel methods of therapeutic hypothermia and the use of cardiac bypass following cardiac arrest," said lead study author David Gaieski, M.D., an associate professor of Emergency Medicine in the Perelman School of Medicine and clinical director of Penn's Center for Resuscitation Science. "Yet cardiac arrests still take the lives of more than 300,000 Americans each year, and we are continuing to explore how to use new and expanded strategies to help save these patients. Based on the work of our colleagues in Asia, we sought to report our own experience using ECMO for a select set of patients with refractory cardiac arrest and profound shock."

For the study, the research team used a collaborative approach between clinicians in the Department of Emergency Medicine and surgeons within the Division of Cardiovascular Surgery at Penn to assess the outcomes for select patients undergoing ECMO presenting in the emergency department (ED) and for in-hospital cardiac arrests at the Hospital of the University of Pennsylvania.

They studied the approach in patients who otherwise would have died — who were unable to be resuscitated through CPR and defibrillation and who would not have been eligible for other post-arrest therapies such as therapeutic hypothermia.

Inclusion criteria for ED patients included witnessed arrest, bystander CPR and an initial shockable rhythm. For in-patient arrests, inclusion criteria included presumed cardiac etiology of arrest or refractory shock unresponsive to conventional interventions. Main variables were whether a patient was in cardiac arrest or profound shock and location of patient at time of initiation of ECMO, with the primary outcome of survival to hospital discharge.

Thirty-three patients were included in the study. Of these patients, the mean age was 50 years and 70 percent were men. Three-quarters of the patients were treated for cardiac arrest, and the remainder were treated for refractory shock. Using the ECMO strategy, 21 percent of the patients survived to discharge and five were neurologically intact.

"This preliminary study shows that using ECMO in a collaborative model between emergency physicians and cardiothoracic surgeons can be a useful rescue tool in select cardiac arrest and shock patients. The results are promising given that among patients that regain a pulse after cardiac arrest, only one out of three survive to hospital discharge," said senior study author Michael Acker, M.D., chief, Division of Cardiovascular Surgery at Penn Medicine.

For more information: www.uphs.upenn.edu

Related Content

St. Jude Medical, HeartMate 3 LVAS, LVAD, CardioStim-EHRA Europace Innovation Award 2016
News | Ventricular Assist Devices (VAD)| June 29, 2016
St. Jude Medical Inc. recently announced the company received an Innovation Award for its HeartMate 3 Left Ventricular...
Feature | Business| April 28, 2016 | Dave Fornell
 
Abiomed, Impella, FDA approval, cardiogenic shock
Technology | Ventricular Assist Devices (VAD)| April 11, 2016
Abiomed Inc. announced that it has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for its...
SynCardia Total Artificial Heart, TAH-t, documentary, Retro Reports, The New York Times
News | Artificial Heart| March 24, 2016
March 24, 2016 — A new documentary produced by Retro Report for The New York Times looks at the history and
News | Ventricular Assist Devices (VAD)| January 08, 2016
XENiOS announced that its i-COR Synchronized Cardiac Assist system protects left ventricular (LV) function compared to...
Feature | Ventricular Assist Devices (VAD)| December 28, 2015
December 28, 2015 — National Cheng Kung University (NCKU) in Taiwan and Duke University School of Medicine are collab
MC3 Cardiopulmonary, acquisition, Terumo Cardiovascular Systems, new manufacturing facility, surgical cannula

Image courtesy of MC3 Cardiopulmonary

News | Cardiovascular Surgery| November 10, 2015
MC3 Cardiopulmonary announced it has completed the acquisition and transfer of all assets associated with Terumo...
Sponsored Content | Videos | TCT| November 05, 2015
DAIC Editor Dave Fornell offers his choices for the most innovative new interventional cardiovascular technologies pr
Heartmate PHP
News | Hemodynamic Support Devices| October 30, 2015
October 30, 2015 — Results from the SHIELD I (Coronary InterventionS in HIgh-Risk PatiEnts Using a Novel Percutaneous
Sponsored Content | Videos | Heart Failure| October 30, 2015
Manesh Patel, M.D., associate professor of medicine, and director of interventional cardiology and the cath labs at D
Overlay Init